This AI trading robot, available at Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA), was a top performer in our robot factory, generating 21% for XRAY over the past 6 months.
DENTSPLY SIRONA (XRAY, $41.09) was one of the top gainers in the medical specialties industry this month, soaring +13.37% to $41.09 per share. The company's stock moved above its 50-day moving average on March 24, 2023, signaling a shift from a downward trend to an upward trend. With an impressive 73% chance of continued upward momentum, investors are paying close attention to XRAY's recent success.
A.I.dvisor analyzed 501 stocks in the medical specialties industry for the month ending April 21, 2023. It discovered that 413 of them (82.47%) exhibited an uptrend, while 88 of them (17.53%) exhibited a downtrend. This bullish industry-wide trend, with over 82% of stocks in an uptrend, sets a positive tone for XRAY's performance.
XRAY's recent move above its 50-day moving average on March 24, 2023, is a significant technical indicator. This shift suggests that the stock is moving from a downward trend to an upward trend, which is generally seen as a bullish signal. In 32 of 44 similar past instances, the stock price increased further within the following month. Based on this historical data, the odds of a continued upward trend are 73%.
DENTSPLY SIRONA's upward trend can be attributed to several factors, including strong earnings results. The company's financial performance indicates that it is well-positioned to capitalize on the positive momentum in the medical specialties industry. As XRAY continues to innovate and expand its product offerings, investors can expect the stock to remain an attractive option in this thriving market sector.
DENTSPLY SIRONA's impressive +13.37% gain this month is a testament to the company's strong position within the medical specialties industry. As the stock continues to rise above its 50-day moving average, investors have reason to be optimistic about XRAY's future performance. With a 73% chance of continued upward momentum, the stock is poised for further growth, making it an appealing investment opportunity for those looking to capitalize on the bullish trend in the medical specialties sector.
The Aroon Indicator for XRAY entered a downward trend on September 19, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 160 similar instances where the Aroon Indicator formed such a pattern. In of the 160 cases the stock moved lower. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on September 05, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on XRAY as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for XRAY turned negative on September 05, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in of 340 cases, the price rose further within the following month. The odds of a continued upward trend are .
XRAY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.010) is normal, around the industry mean (24.999). P/E Ratio (19.231) is within average values for comparable stocks, (80.409). Projected Growth (PEG Ratio) (1.924) is also within normal values, averaging (6.287). Dividend Yield (0.015) settles around the average of (0.018) among similar stocks. P/S Ratio (1.917) is also within normal values, averaging (59.144).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XRAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a global denal eqipment company
A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.